Filing Coverage: Why Formanek Investment Trust Reported Big Gtx Inc Position?

Filing Coverage: Why Formanek Investment Trust Reported Big Gtx Inc  Position?

The New Formanek Investment Trust Holding in Gtx Inc

Formanek Investment Trust filed with the SEC SC 13G/A form for Gtx Inc . The form can be accessed here: 000114036116088426. As reported in Formanek Investment Trust’s form, the filler as of late owns 5.48% or 7,896,505 shares of the Health Care–company.

Gtx Inc stake is a new one for the and it was filed because of activity on October14,2016. We feel this shows Formanek Investment Trust’s positive view for the stock.

Gtx Inc Institutional Sentiment

Latest Security and Exchange filings show 39 investors own Gtx Inc . The institutional ownership in Q3 2015 is low, at 11.89% of the outstanding shares. This is increased by 4626148 the total institutional shares. 18932763 were the shares owned by these institutional investors. In total 5 funds opened new Gtx Inc stakes, 8 increased stakes. There were 6 that closed positions and 9 reduced them.

Delta Asset Management Llc is an institutional investor bullish on Gtx Inc , owning 18800 shares as of Q3 2015 for less than 0.01% of its portfolio. J. Carlo Cannell Cannell Peter B & Company Inc owns 20000 shares or less than 0.01% of its portfolio. NJ Fcg Advisors Llc have 0.01% of their stock portfolio for 23478 shares. Further, Td Capital Management Llc reported stake worth less than 0.01% of its US stock portfolio. The CA Bvf Inc owns 10772306 shares. Gtx Inc is 1.65% of the manager’s US portfolio.

Business Profile

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 0.92 in 2016 Q2. Its up 0.25, from 0.67 in 2016Q1. The ratio improved, as 5 funds sold all GTx, Inc. shares owned while 7 reduced positions. 3 funds bought stakes while 5 increased positions. They now own 15.20 million shares or 0.70% less from 15.31 million shares in 2016Q1.

Bancorp Of Mellon Corp has 0% invested in the company for 39,529 shares. Ftb Advisors has 128,000 shares for 0.01% of their US portfolio. Wells Fargo Company Mn accumulated 0% or 3,500 shares. Td Cap Management Lc holds 0% of its portfolio in GTx, Inc. (NASDAQ:GTXI) for 100 shares. Moreover, Highland Capital Mngmt Limited Liability Com has 0% invested in GTx, Inc. (NASDAQ:GTXI) for 14,234 shares. Fcg Advisors Limited Liability has invested 0% of its portfolio in GTx, Inc. (NASDAQ:GTXI). Morgan Stanley has invested 0% of its portfolio in GTx, Inc. (NASDAQ:GTXI). Blackrock Fund Advisors last reported 0% of its portfolio in the stock. Stifel Financial Corporation accumulated 0% or 50,000 shares. The United Kingdom-based Barclays Pcl has invested 0% in GTx, Inc. (NASDAQ:GTXI). Citigroup, a New York-based fund reported 5,300 shares. The Ontario – Canada-based Royal Bancorp Of Canada has invested 0% in GTx, Inc. (NASDAQ:GTXI). Moreover, Kcg has 0% invested in GTx, Inc. (NASDAQ:GTXI) for 10,500 shares. D E Shaw And Com reported 136,786 shares or 0% of all its holdings. Blackrock Institutional Trust Co Na has 1.53M shares for 0% of their US portfolio.

Analysts await GTx, Inc. (NASDAQ:GTXI) to report earnings on March, 2. They expect $-0.03 EPS, up 50.00% or $0.03 from last year’s $-0.06 per share. After $-0.05 actual EPS reported by GTx, Inc. for the previous quarter, Wall Street now forecasts -40.00% EPS growth.

The stock decreased 1.23% or $0.01 on December 1, hitting $0.8. About 68,485 shares traded hands. GTx, Inc. (NASDAQ:GTXI) has risen 15.71% since April 28, 2016 and is uptrending. It has outperformed by 9.79% the S&P500.

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The company has a market cap of $126.58 million. The Firm is engaged in the development of selective androgen receptor modulators . It currently has negative earnings. The Company’s lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials.

Another recent and important GTx, Inc. (NASDAQ:GTXI) news was published by Streetinsider.com which published an article titled: “GTx, Inc. (GTXI) Announces Enobosarm Met pre-Specified Primary Efficacy …” on November 28, 2016.

According to Zacks Investment Research, “GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx’s lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.”

GTXI Company Profile

GTx, Inc., incorporated on October 4, 2003, is a biopharmaceutical firm focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Firm is engaged in the development of selective androgen receptor modulators (SARMs). The Company’s lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials, enrolling approximately 1,500 subjects, of which approximately 1,000 subjects were treated with enobosarm. The Firm is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment